Stock Analiz

ABBV vs MRK stock comparison

AbbVie vs. Merck & Co. · data as of November 13, 2026

AbbVie (ABBV) has a market value of about $521.5B, Merck & Co. (MRK) about $364.3B. Over their latest twelve months AbbVie had revenue of $66.0B and Merck & Co. $67.4B.

On our five checks Merck & Co. scores higher: 2.8 out of 5 (average) against 1.8 (weak).

By area, the stronger company is Merck & Co. on future growth; Merck & Co. on track record; Merck & Co. on shareholder returns.

AbbVie is cheaper on earnings (P/E 50.8 vs. 150.8), while Merck & Co. grew revenue faster over five years (9.4% vs. 5.9% a year).

AbbVie leads on 8 of the compared lines and Merck & Co. on 14.

Side by side

ABBVMRK
Size and price
Market cap$521.5B$364.3B
Share price$295.03$147.76
Score
Overall score (of 5)1.82.8
Value00
Future growth12
Track record25
Financial health22
Shareholder returns45
Valuation
P/E (TTM)50.8150.8
Forward P/E19.117.6
Price / free cash flow27.624.7
Price / sales7.95.4
EV / EBITDA19.832.5
PEG—7.10
DCF value vs. price−20%−31%
Business
Revenue$66.0B$67.4B
Net income$10.3B$2.5B
Free cash flow$18.9B$14.7B
Net margin15.7%3.6%
Gross margin (5-yr avg.)68.3%73.4%
ROIC (5-yr avg.)15.3%16.3%
Growth
Revenue growth (1 yr)8.6%1.3%
Revenue growth (5 yrs, per year)5.9%9.4%
EPS growth (5 yrs, per year)-2.8%21.2%
Balance sheet and payouts
Net cash (cash minus debt)-$61.5B-$44.1B
Dividend yield2.35%2.30%
Shareholder yield2.5%3.7%
Analysts
Upside to average target+6%+9%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: ABBV TTM to September 30, 2026, MRK TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, AbbVie or Merck & Co.?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and AbbVie 1.8; the table shows where each one is stronger.

Is AbbVie cheaper than Merck & Co.?

On trailing earnings, AbbVie trades at a P/E of 50.8 and Merck & Co. at 150.8, so AbbVie is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, AbbVie or Merck & Co.?

Over five years Merck & Co. grew revenue about 9.4% a year and AbbVie about 5.9% a year.

Which pays a higher dividend?

AbbVie yields 2.35% and Merck & Co. 2.30%.

Full AbbVie analysis → Full Merck & Co. analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.